Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.23.3
Commitments and Contingencies (Details Narrative) - USD ($)
9 Months Ended
Feb. 06, 2021
Sep. 30, 2023
Sep. 30, 2022
Apr. 30, 2023
Mar. 29, 2023
Dec. 31, 2022
Houston Pharmaceuticals [Member]            
Product Liability Contingency [Line Items]            
Cost of goods and services sold   $ 0 $ 41,075      
Officers [Member]            
Product Liability Contingency [Line Items]            
Cash bonuses approved         $ 550,750  
Scientific Advisory Board [Member]            
Product Liability Contingency [Line Items]            
Labour and related expense   0 76,087      
Mr Hsu Scientific Advisory Board [Member]            
Product Liability Contingency [Line Items]            
Accrued related to compensation   151,584        
Houston Pharm [Member] | Technology Rights Agr [Member]            
Product Liability Contingency [Line Items]            
Royalty income, nonoperating   37,500 262,500      
Pum [Member]            
Product Liability Contingency [Line Items]            
Accounts receivable   197,605   $ 196,303   $ 1,302
U T M D A C C [Member] | Patent And Technology License Agr [Member]            
Product Liability Contingency [Line Items]            
License fee   $ 45,092 $ 49,607      
Mr Climaco [Member]            
Product Liability Contingency [Line Items]            
Annual base salary $ 525,000